Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
To determine the safety and tolerability of ACP-104 after oral administration of single doses
in comparison with placebo to schizophrenia or other psychotic disorders.
Phase:
Phase 1
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
ACADIA Pharmaceuticals Inc. Stanley Medical Research Institute